Venue
GE Medical Systems • Radiology • 06/27/2022
Device Purpose
The Venue system is a mobile diagnostic ultrasound device utilizing pulsed doppler and echo imaging technology for a broad range of clinical applications, enhanced with features like the AI-driven cNerve tool for improved nerve visualization during adult procedures. Its purpose is to provide clinicians with a versatile, user-friendly imaging solution with automated tools, expanded pediatric applications, and updated processing capabilities to support efficient diagnosis and interventional procedures at the point of care.
Summary
The Venue system is a mobile, general-purpose diagnostic ultrasound device intended for comprehensive imaging, measurement, and analysis of the human body and fluids across various clinical settings like hospitals and clinics. It employs digital acquisition, processing, and display, featuring a high-resolution touchscreen monitor, ECG synchronization for gating, battery operation for portability, wireless connectivity, and DICOM support. Utilizing a range of linear, convex, and phased array transducers, the Venue supports multiple imaging modes (including B-Mode, M-Mode, PW/CW Doppler, Color Doppler, Harmonic Imaging) and is designed for diverse clinical applications such as abdominal, thoracic/pleural, ophthalmic, fetal/OB, small organ, vascular, pediatric, musculoskeletal, cardiac, transrectal, transvaginal, transesophageal, intraoperative, and interventional guidance, including new nonvascular access applications for specific transducers and an ophthalmic application for the M5Sc-RS transducer. This updated Venue system incorporates a new back-end accelerated processing unit and introduces several software enhancements aimed at improving workflow and diagnostic capabilities. Notable new features include "Scribble" for training, "Power Doppler Imaging+" (PDI+) for visualizing slow blood flows, "Catheter Vessel Ratio" for catheter sizing, "Probe Check" for transducer maintenance, "Shoulder Diagram" for orthopedic documentation, and "cNerve," an AI-powered tool for detecting and tracking nerves during adult nerve block procedures. The system also expands its B-lines assessment tool and Real-Time Ejection Fraction measurement to pediatric patients (excluding neonates), and adds accessories like specific biopsy guides and an RFID scanner. Non-clinical testing confirmed the device's safety and performance, with the cNerve AI tool demonstrating accuracy against expert annotations on a diverse dataset of 124 sequences from 44 individuals across varied demographics and supported probe types.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the "cNerve" AI algorithm's performance compare in differentiating nerve tissue from surrounding similar-echogenicity tissues, especially in patients with high BMI or complex anatomy?; What is the quantitative impact of the "Power Doppler Imaging+" (PDI+) feature on the detection sensitivity for slow blood flow compared to standard Power Doppler, particularly in specific anatomical regions like small joints?; Are there plans to expand the "cNerve" tool's application to pediatric patients or for nerve block procedures in anatomical regions beyond those currently supported?; What specific workflow improvements were implemented in the software updates, and how do these translate to measurable time savings or enhanced usability for clinicians in point-of-care settings?; Considering the expansion of B-lines tool and Real-Time Ejection Fraction to pediatrics, what validation data supports its accuracy and reliability in this specific patient population, excluding neonates?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly